Merck is heading into its second-quarter earnings report on Tuesday with important pillars of its business increasingly under ...

Fact checked by Jennifer Klump Despite its proven ability to prevent cancers, the HPV vaccine remains underused in the United ...

HHS Secretary Robert F. Kennedy Jr. said he's going to "fix" the nation's Vaccine Injury Compensation Program (VICP).

US Health and Human Services Secretary Robert F. Kennedy Jr. said Monday that he is working with the Justice Department to ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a ...

Merck issued guidance for 2025 that lags consensus amid struggles in China with Gardasil . Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 ...

Merck said it had stopped Gardasil shipments to China from this month. The company has previously said China's anti-bribery and anti-corruption drive had also hurt sales of the vaccine.

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 yuan ($70) per dose, the state-owned Xinhua News Agency reports.

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...